Vera Therapeutics, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address 2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE, CA, 94005
Mailing Address 2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE, CA, 94005
Phone 650-770-0077
Fiscal Year End 1231
EIN 812744449
Financial Overview
FY2024
$655.68M
Total Assets
$78.53M
Total Liabilities
$101.69M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | February 6, 2026 | View on SEC |
| 4 Insider stock transaction report | February 6, 2026 | View on SEC |
| 4 Insider stock transaction report | February 6, 2026 | View on SEC |
| 4 Insider stock transaction report | February 6, 2026 | View on SEC |
| 4 Insider stock transaction report | February 6, 2026 | View on SEC |
| 4 Insider stock transaction report | February 6, 2026 | View on SEC |
| 4 Insider stock transaction report | February 6, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 5, 2026 | View on SEC |
| 3 Initial insider ownership report | January 30, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | January 30, 2026 | View on SEC |
Insider Trading
STRONG SELL 3 insiders
5 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.